- No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
OBIO
NASDAQ
Week ended 24 Jul 2026
Weekly Investor Report
Orchestra BioMed Holdings Inc. · Healthcare · Biotechnology
Latest close
3.74 USD
1.6%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is -8.8% below the Trend Line and sits at 47.8% of its 52-week range. The latest completed week returned 1.6%, after a -11.8% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is mixed with 30/100 conviction, while the latest news-sentiment score is 54/100. Near-term considerations: volume confirmation is below normal; earnings are due in 8d.
Setup score
25
out of 100
Latest Close
3.74 USD
24 Jul 2026
1W Return
1.6%
latest completed week
4W Return
-11.8%
short-term follow-through
12W Return
-5.8%
quarterly tape
Trend Breadth
53.8%
28 of 52 weeks active
Volume Ratio
0.6x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
1.6%
Latest completed week; four-week move -11.8%.
Indicator stack
30/31
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Options pressure
Mixed
30/100 conviction; expected move 36.9%.
News sentiment
54/100
54 relevant articles in the latest sentiment read.
Event risk
8d
Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -8.8% below the Trend Line and sits at 47.8% of its 52-week range. The latest completed week returned 1.6%, after a -11.8% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.6x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
30 Jan
6 Feb
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.3212-week average 0.32
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.32Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -11.8% over four weeks, -5.8% over 12 weeks, and 13.7% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year28
Trend breadth53.8%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-0.83Latest activity-pressure read.
Pressure change-55.1%Four-week change in activity pressure.
Leadership-9.93Latest relative-leadership reading.
RS change-867.4%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 26 Jul 2026
Financial statements through 31 Dec 2025
Field coverage 82%
Model confidence 78%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength47/100Blend of value, momentum, and quality. Underlying universe rank 54; rank 1 is best.
Value48/100Relative valuation strength. Underlying universe rank 53; rank 1 is best.
Quality46/100Profitability and accounting quality. Underlying universe rank 55; rank 1 is best.
Momentum48/100Medium-term price momentum. Underlying universe rank 53; rank 1 is best.
Growth48/100Revenue and earnings growth. Underlying universe rank 53; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 6.8x Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -23.5% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 99.3% Gross profit retained from each unit of revenue.
- Operating margin
- -162.1% Operating profit retained from revenue.
- Free-cash-flow margin
- -164.9% Free cash flow generated from revenue.
- Return on invested capital
- -70.8% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- - Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 6/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -32.1% Net share repurchases relative to market value.
- Shareholder yield
- -32.1% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- -0.1x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Options positioningMixed
OBIO shows mixed options pressure with a 30/100 conviction score, put-call volume ratio of n/a, expected move of 36.9%, and Sharemaestro trend signal inactive.
Conviction30/100
Expected move36.9%
Put/call volume
Insider activity-
No recent insider transactions are stored for this company.
News sentiment54/100
Weighted news tone is neutral across 54 relevant articles.
14 positive · 35 neutral · 5 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings8dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
Options expected move36.9%Nearest-chain priced movement where available.
52-week drawdown-31.0%Distance below the 52-week high.
13-week volatility5.1%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
30 Jan
27 Feb
27 Mar
24 Apr
22 May
19 Jun
24 Jul
Weeks higher11 of 2615 weeks finished lower.
Best week+12.0%Week of 6 Feb.
Worst week-13.6%Week of 30 Jan.
Latest week+1.6%Week of 24 Jul.
Shape of recent returns
Strong gains7
Modest gains4
Flat weeks0
Modest losses9
Sharp losses6
Recent vol5.1%13-week weekly-return volatility.
Base vol8.9%52-week weekly-return volatility.
Up/down split23/29Count of positive and negative weeks in the 52-week window.
Average skew8.4% / -5.5%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average1.3%
Trend breadth51.0%
Trend51.0%active weekly trend signals
MD75.0%positive activity pressure
RS48.0%positive relative leadership
Four-week leaders
IndustryUS Biotechnology
4-week rank- / 100
Group average0.5%
Trend breadth67.0%
Trend67.0%active weekly trend signals
MD72.0%positive activity pressure
RS65.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape27/100
Trend, activity pressure, participation, and risk combine to a 27/100 tape read.
Indicator analysis14/100Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.
Activity pressure 0.32; No reversal markers Factors46/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 94; Small Cap Core rank 56 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Options48/100OBIO shows mixed options pressure with a 30/100 conviction score, put-call volume ratio of n/a, expected move of 36.9%, and Sharemaestro trend signal inactive.
Mixed · Options-market disagreement · Expected move 36.9% Sentiment54/100Weighted news tone is neutral across 54 relevant articles.
OBIO|Orchestra Biomed Holdings Inc|Price:3.825|Chg%:+0.085 Insiders50/100No recent insider transaction evidence is stored.
Earnings8dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 24 Jul 2026 | 3.74 USD | 1.6% | 4.10 USD | 5.01 USD | -0.83 | -9.93 | 908.5K | Off |
| 17 Jul 2026 | 3.68 USD | -7.8% | 4.12 USD | 5.02 USD | -0.55 | -12.89 | 1.2M | Off |
| 10 Jul 2026 | 3.99 USD | -4.8% | 4.14 USD | 5.05 USD | -0.42 | -9.55 | 1.2M | Off |
| 3 Jul 2026 | 4.19 USD | -1.2% | 4.16 USD | 5.07 USD | -0.35 | -3.23 | 1.6M | Off |
| 26 Jun 2026 | 4.24 USD | 6.3% | 4.16 USD | 5.08 USD | -0.54 | -1.03 | 6.1M | Off |
| 19 Jun 2026 | 3.99 USD | -2.7% | 4.20 USD | 5.10 USD | -0.73 | -10.80 | 1.2M | Off |
| 12 Jun 2026 | 4.10 USD | 5.1% | 4.22 USD | 5.13 USD | -0.61 | -5.99 | 1.3M | Off |
| 5 Jun 2026 | 3.90 USD | -0.3% | 4.21 USD | 5.16 USD | -0.62 | -8.57 | 1.0M | Off |
| 29 May 2026 | 3.91 USD | -3.7% | 4.21 USD | 5.23 USD | -0.42 | -12.67 | 804.4K | Off |
| 22 May 2026 | 4.06 USD | 9.1% | 4.21 USD | 5.30 USD | -0.27 | -6.76 | 1.5M | Off |
| 15 May 2026 | 3.72 USD | -7.9% | 4.21 USD | 5.37 USD | -0.28 | -13.45 | 1.6M | Off |
| 8 May 2026 | 4.04 USD | 1.8% | 4.19 USD | 5.45 USD | -0.15 | -6.40 | 1.2M | Off |
| 1 May 2026 | 3.97 USD | -3.9% | 4.16 USD | 5.53 USD | -0.24 | -2.90 | 1.2M | On |
| 24 Apr 2026 | 4.13 USD | -9.8% | 4.12 USD | 5.61 USD | -0.26 | 2.67 | 880.3K | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.